Phase II efficacy data for NGM Biopharmaceuticals’ developmental non-alcoholic steatohepatitis (NASH) drug, NGM282,...
- ILC 2018: NGM’s intravenous NASH therapy shows rapid reduction in liver fat content and fibrosis
- CD40 agonist developments could support Anti-PD-(L)1 therapy in pancreatic cancer
- ILC 2018: Allergan’s cenicriviroc shows continued fibrosis response in NASH patients in two year extended study
- Oral pill to treat psoriasis: could this be a game-changer?
- Stem cell therapies could reduce effects of stroke-related disability
ILC 2018: NGM’s intravenous NASH therapy shows rapid reduction in liver fat content and fibrosis
Phase II efficacy data for NGM Biopharmaceuticals’ developmental non-alcoholic steatohepatitis (NASH) drug, NGM282, was presented at the 2018 International Liver Congress (ILC) in Paris, France.
Merck to begin two Phase III trials of PCV-15 (V114)
Merck is set to commence two new Phase III studies of PCV-15 (V114), an investigational polyvalent conjugate vaccine to prevent pneumococcal disease.
Fervent begins Phase IIa trial of FP-101 for vasomotor symptoms
Fervent Pharmaceuticals has initiated a Phase IIa clinical trial to investigate the therapeutic potential of FP-101 in treating vasomotor symptoms, including hot flashes, night sweats and insomnia, in post-menopausal women.
Asahi starts enrolment in Phase III trial of isavuconazole
Asahi Kasei Pharma has started enrolling patients in a Phase III trial of isavuconazole to treat deep-seated mycosis, comprised of invasive aspergillosis, chronic pulmonary aspergillosis, mucormycosis and cryptococcosis.
AstraZeneca announces OS data from breast cancer treatment Lynparza
AstraZeneca and Merck have announced overall survival (OS) data from Phase III trial OlympiAD examining Lynparza (olaparib) as a treatment for metastatic breast cancer.
CD40 agonist developments could support Anti-PD-(L)1 therapy in pancreatic cancer
A major theme of this year’s AACR meeting examines the approaches that aim to further improve the anti-tumour efficacy of anti-PD-1 and –PD-L1 checkpoint inhibitors (CPIs) in the clinic.
Idera Pharmaceuticals to conduct three trials of IMO-2125
Idera Pharmaceuticals has signed a clinical development support agreement with Pillar Partners Foundation for carrying out three trials of IMO-2125, a toll-like receptor (TLR) 9 agonist that can target melanoma and other solid tumours.
Novartis reports positive outcome in LIBERTY trial
Novartis has reported positive results in the LIBERTY trial, a Phase IIIb study investigating the safety and efficacy of Aimovig (erenumab) in patients with episodic migraine who had previously failed two to four preventive treatments for migraine.
Herantis reports positive interim data for gene therapy Lymfactin
Herantis Pharmaceuticals has announced positive results from a safety evaluation of its Phase I clinical trial of Lymfactin, the company’s investigational gene therapy product, as a treatment for secondary lymphoedema.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.